Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | TBXAS1 | P24557 | 10/20 | 0.47 |
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | CFTR | P13569 | 1/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.43 |
| ▸ | GOPC | Q9HD26 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20940017 | 1.00 | L3MBTL1 (0.50) | L3MBTL1TDP1TBXAS1LMNAPOLB | |
| SCHEMBL18842833 | 1.00 | L3MBTL1 (0.50) | L3MBTL1TDP1TBXAS1LMNAPOLB | |
| SCHEMBL25003559 | 1.00 | L3MBTL1 (0.50) | L3MBTL1TDP1TBXAS1LMNAPOLB | |
| SCHEMBL14028947 | 0.98 | L3MBTL1 (0.49) | L3MBTL1TDP1TBXAS1LMNAPOLB | |
| SCHEMBL18848784 | 0.98 | L3MBTL1 (0.49) | L3MBTL1TDP1TBXAS1LMNAPOLB | |
| SCHEMBL18473557 | 0.98 | L3MBTL1 (0.51) | L3MBTL1TDP1TBXAS1LMNAPOLB | |
| SCHEMBL18910475 | 0.97 | L3MBTL1 (0.47) | L3MBTL1TDP1TBXAS1LMNAPOLB | |
| SCHEMBL25067012 | 0.97 | L3MBTL1 (0.47) | L3MBTL1TDP1TBXAS1LMNAPOLB | |
| SCHEMBL26751590 | 0.97 | L3MBTL1 (0.50) | L3MBTL1TDP1TBXAS1LMNACFTR | |
| Hydrochloric Acid SCHEMBL29251873 | 0.95 | L3MBTL1 (0.46) | L3MBTL1TDP1TBXAS1LMNAPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11752149-B2 | Muscarinic acetylcholine M1 receptor antagonists | Pipeline Therapeutics, Inc. (US) | 2023-09-12 | — | — | US | disclosed |
| US-20230250106-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2023-08-10 | — | — | US | disclosed |
| US-20230159543-A1 | ANTHELMINTIC PYRROLOPYRIDAZINE COMPOUNDS | BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) | 2023-05-25 | — | — | US | disclosed |
| US-20230045142-A1 | SMALL MOLECULE RPN13 INHIBITORS WITH ANTITUMOR PROPERTIES | THE JOHNS HOPKINS UNIVERSITY (US) | 2023-02-09 | — | — | US | disclosed |
| US-20230031406-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2023-02-02 | — | — | US | disclosed |
| US-20230011652-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2023-01-12 | — | — | US | disclosed |
| US-11352343-B2 | Urea derivatives and uses thereof | KALA PHARMACEUTICALS, INC. (US) | 2022-06-07 | — | — | US | disclosed |
| US-20220169613-A1 | Drp1-FILAMIN COMPLEX FORMATION INHIBITORS | Rdiscovery, LLC | 2022-06-02 | — | — | US | disclosed |
| US-20220162186-A1 | PROSTAGLANDIN RECEPTOR EP2 ANTAGONISTS, DERIVATIVES, AND USES RELATED THERETO | EMORY UNIVERSITY | 2022-05-26 | — | — | US | disclosed |
| US-20210161889-A1 | MUSCARINIC ACETYLCHOLINE M1 RECEPTOR ANTAGONISTS | CONTINEUM THERAPEUTICS, INC. | 2021-06-03 | — | — | US | disclosed |
| US-10351570-B2 | Compounds and uses thereof | KALA PHARMACEUTICALS, INC. (US) | 2019-07-16 | — | — | US | disclosed |
| US-10316022-B2 | Urea derivatives and uses thereof | KALA PHARMACEUTICALS, INC. (US) | 2019-06-11 | — | — | US | disclosed |
| US-10294243-B2 | Bicyclic compounds as pesticides | BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) | 2019-05-21 | — | — | US | disclosed |
| US-10023536-B2 | Suprametallogels and uses thereof | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2018-07-17 | — | — | US | disclosed |
| US-20180037572-A1 | UREA DERIVATIVES AND USES THEREOF | KALA BIO, Inc. | 2018-02-08 | — | — | US | disclosed |
| US-9790180-B2 | Piperidine derivatives as HDAC1/2 inhibitors | REGENACY PHARMACEUTICALS, LLC (US) | 2017-10-17 | — | — | US | disclosed |
| US-9669046-B2 | Biodefenses using triazole-containing macrolides | CEMPRA PHARMACEUTICALS, INC. (US) | 2017-06-06 | — | — | US | disclosed |
| US-20170101422-A1 | Bicyclic compounds as pesticides | BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) | 2017-04-13 | — | — | US | disclosed |
| US-20170073311-A1 | SUPRAMETALLOGELS AND USES THEREOF | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2017-03-16 | — | — | US | disclosed |
| US-9580421-B2 | Urea derivatives and uses thereof | KALA PHARMACEUTICALS, INC. (US) | 2017-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (17 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220169613-A1 | Drp1-FILAMIN COMPLEX FORMATION INHIBITORS | FIS1, DNM1L, DNM1 | L3MBTL1 4525/4885TDP1 757/4885TBXAS1 3714/4885 |
| US-20230031406-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NLRP1, NLRP3, NOD1 | L3MBTL1 4789/4885TDP1 1532/4885TBXAS1 636/4885 |
| US-20230250106-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | STING1, CGAS, IRF3 | L3MBTL1 2331/4885TDP1 75/4885TBXAS1 202/4885 |
| US-10316022-B2 | Urea derivatives and uses thereof | UACA, RB1, FLT1 | L3MBTL1 4827/4885TDP1 3546/4885TBXAS1 2117/4885 |
| US-11352343-B2 | Urea derivatives and uses thereof | UACA, RB1, FLT1 | L3MBTL1 4827/4885TDP1 3546/4885TBXAS1 2117/4885 |
| US-20230011652-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NLRP1, NLRP3, NOD1 | L3MBTL1 4782/4885TDP1 1513/4885TBXAS1 647/4885 |
| US-20180037572-A1 | UREA DERIVATIVES AND USES THEREOF | UACA, RB1, FLT1 | L3MBTL1 4827/4885TDP1 3546/4885TBXAS1 2117/4885 |
| US-11752149-B2 | Muscarinic acetylcholine M1 receptor antagonists | CHRM1, CHRM2, CHRM5 | L3MBTL1 1260/4885TDP1 1551/4885TBXAS1 2463/4885 |
| US-20220162186-A1 | PROSTAGLANDIN RECEPTOR EP2 ANTAGONISTS, DERIVATIVES, AND USES RELATED THERETO | PTGER2, PTGES2, PTGES | L3MBTL1 4867/4885TDP1 3360/4885TBXAS1 191/4885 |
| US-20230159543-A1 | ANTHELMINTIC PYRROLOPYRIDAZINE COMPOUNDS | IL5, EPX, MPO | L3MBTL1 4043/4885TDP1 3020/4885TBXAS1 2183/4885 |
| US-10023536-B2 | Suprametallogels and uses thereof | PDCD1LG2, PDCD2L, PYGL | L3MBTL1 513/4885TDP1 2137/4885TBXAS1 1825/4885 |
| US-20210161889-A1 | MUSCARINIC ACETYLCHOLINE M1 RECEPTOR ANTAGONISTS | CHRM1, CHRM2, CHRM5 | L3MBTL1 1260/4885TDP1 1551/4885TBXAS1 2463/4885 |
| US-10294243-B2 | Bicyclic compounds as pesticides | DDT, BCHE, CYCS | L3MBTL1 340/4885TDP1 2969/4885TBXAS1 3214/4885 |
| US-20170101422-A1 | Bicyclic compounds as pesticides | DDT, BCHE, CYCS | L3MBTL1 340/4885TDP1 2969/4885TBXAS1 3214/4885 |
| US-20170073311-A1 | SUPRAMETALLOGELS AND USES THEREOF | PDCD1LG2, PDCD2L, PYGL | L3MBTL1 513/4885TDP1 2137/4885TBXAS1 1825/4885 |
| US-10351570-B2 | Compounds and uses thereof | RB1, VEGFA, FLT4 | L3MBTL1 4854/4885TDP1 3830/4885TBXAS1 1794/4885 |
| US-20230045142-A1 | SMALL MOLECULE RPN13 INHIBITORS WITH ANTITUMOR PROPERTIES | MRPS23, RPP30, RPS19 | L3MBTL1 1159/4885TDP1 2524/4885TBXAS1 3116/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.